TY - JOUR
T1 - A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia
T2 - recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group
AU - Maqbool, M. Gohar
AU - Tam, Constantine S.
AU - Morison, Ian M.
AU - Simpson, David
AU - Mollee, Peter
AU - Schneider, Hans
AU - Chan, Henry
AU - Juneja, Surender
AU - Harvey, Yasmin
AU - Nath, Lakshmi
AU - Hissaria, Pravin
AU - Prince, H. Miles
AU - Wordsworth, Helen
AU - Opat, Stephen
AU - Talaulikar, Dipti
PY - 2020/2
Y1 - 2020/2
N2 - Waldenström macroglobulinaemia (WM) is an indolent non-Hodgkin lymphoma which usually presents with symptoms related to infiltration of bone marrow or other tissues like lymph nodes, liver or spleen and has certain unusual clinical manifestations, e.g., renal and central nervous system (CNS) involvement. It also has an array of laboratory features including hypersecretion of IgM, cryoglobulinaemia, increased plasma viscosity and identification of mutated MYD88L265P in more than 90% of cases. In this review, we aim to provide a guide to the laboratory investigations recommended for WM at initial diagnosis and at follow-up. A discussion on the nuances of diagnosis and differential diagnoses is followed by bone marrow (BM) assessment, measurement of paraprotein and other ancillary investigations. Recommendations are provided on laboratory work-up at diagnosis, in the asymptomatic follow-up phase, and during and post-treatment. Finally, we briefly discuss the implications of laboratory diagnosis in regard to recruitment and monitoring on clinical trials.
AB - Waldenström macroglobulinaemia (WM) is an indolent non-Hodgkin lymphoma which usually presents with symptoms related to infiltration of bone marrow or other tissues like lymph nodes, liver or spleen and has certain unusual clinical manifestations, e.g., renal and central nervous system (CNS) involvement. It also has an array of laboratory features including hypersecretion of IgM, cryoglobulinaemia, increased plasma viscosity and identification of mutated MYD88L265P in more than 90% of cases. In this review, we aim to provide a guide to the laboratory investigations recommended for WM at initial diagnosis and at follow-up. A discussion on the nuances of diagnosis and differential diagnoses is followed by bone marrow (BM) assessment, measurement of paraprotein and other ancillary investigations. Recommendations are provided on laboratory work-up at diagnosis, in the asymptomatic follow-up phase, and during and post-treatment. Finally, we briefly discuss the implications of laboratory diagnosis in regard to recruitment and monitoring on clinical trials.
KW - CXCR4
KW - IgM MGUS
KW - IgM paraprotein
KW - laboratory investigations for Waldenström macroglobulinaemia
KW - lymphoplasmacytic lymphoma
KW - MYD88
KW - Practical guide for Waldenström macroglobulinaemia
KW - transformed Waldenström macroglobulinaemia
KW - work-up at diagnosis for Waldenström macroglobulinaemia
KW - work-up for Waldenström macroglobulinaemia during and post treatment
UR - http://www.scopus.com/inward/record.url?scp=85077315929&partnerID=8YFLogxK
U2 - 10.1016/j.pathol.2019.11.002
DO - 10.1016/j.pathol.2019.11.002
M3 - Review Article
C2 - 31902622
AN - SCOPUS:85077315929
SN - 0031-3025
VL - 52
SP - 167
EP - 178
JO - Pathology
JF - Pathology
IS - 2
ER -